logo-loader
viewBioCorRx Inc.

BioCorRx touts early preclinical data for potential fentanyl overdose-reversing drug

The drug, developed in partnership with VDM Biochemicals, could represent an alternative to naloxone in the overdose reversal market

One person looking at someone else out of frame who is holding a pen
The early preclinical data showed that the effects of fentanyl may be completely prevented by VDM-001

BioCorRx Inc (OTCMKTS:BICX) updated investors Tuesday on the development of its drug candidate VDM-001, highlighting early data that suggests it may prevent overdose from fentanyl. 

The drug, developed through a partnership between its subsidiary BioCorRx Pharmaceuticals and VDM Biochemicals Inc, could represent an alternative to naloxone in the overdose reversal market, the company said. 

“Unlike naloxone, VDM-001 is a 100% pure synthetic antagonist, whereas naloxone relies on natural sources for manufacturing,” BioCorRx CEO Brady Granier said in a statement. “New preclinical data coupled with other claims from VDM, suggest therapeutic advantages of VDM-001 over naloxone and support its entry into other areas of unmet medical need. One potential benefit of VDM-001 may be a shorter and less costly manufacturing cycle. We look forward to working with VDM in order to further explore this molecule.”

READ: BioCorRx weight-loss system UnCraveRx to sponsor and present at metabolic conference

The early preclinical data showed that the effects of fentanyl may be completely prevented by VDM-001, the company said. The drug was well tolerated and showed no signs of toxicity. 

“We are very encouraged by the new preclinical data showing the ability of VDM-001 to block analgesic effects of fentanyl in vivo,” VDM CEO David Martirosyan said. “Based upon the data that we have gathered, new studies are currently being conducted to gain more insight into the mechanism of action of VDM-001. We believe that VDM-001 holds a significant potential to become a major lifesaving drug and have a profound impact on the lives of many people affected by the opioid epidemic. We are delighted with the current partnership in place with BioCorRx, and we welcome their continued support in our efforts to advance VDM-001.”

In 2017 alone, Martirosyan said, 28,400 people died of overdoses from synthetic opioids such as fentanyl in the US.

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: BioCorRx Inc.

Price: 3 USD

OTCQB:BICX
Market: OTCQB
Market Cap: $15.9 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BioCorRx Inc. named herein, including the promotion by the Company of BioCorRx Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: BioCorRx presents new preclinical data showing VDM-001...

BioCorRx Inc (OTCMKTS:BICX) CEO Brady Granier tells Proactive early data suggests its drug therapy may prevent overdoses from fentanyl. Granier says while VDM-001 is still in its early days, with more validation studies to come, the drug candidate could represent an alternative to naloxone in...

4 days, 12 hours ago

2 min read